Development of a Physiologically-Based Pharmacokinetic Model for Sirolimus: Predicting Bioavailability Based on Intestinal CYP3A Content

Sirolimus is an inhibitor of mammalian target of rapamycin (mTOR) and is increasingly being used in transplantation and cancer therapies. Sirolimus has low oral bioavailability and exhibits large pharmacokinetic variability. The underlying mechanisms for this variability have not been explored to a...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Emoto, C, Fukuda, T, Cox, S, Christians, U, Vinks, A A
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group 2013
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3731827/
https://ncbi.nlm.nih.gov/pubmed/23884207
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/psp.2013.33
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi